WO2024150146 - ENGINEERED KETOREDUCTASE POLYPEPTIDES
National phase entry:
Publication Number
WO/2024/150146
Publication Date
18.07.2024
International Application No.
PCT/IB2024/050231
International Filing Date
10.01.2024
Title **
[English]
ENGINEERED KETOREDUCTASE POLYPEPTIDES
[French]
POLYPEPTIDES CÉTORÉDUCTASES MODIFIÉS
Applicants **
NOVARTIS AG
Inventors
YE, Ning
HARDEGGER, Leo Albert
HUEBER, Lukas Simon
LEEMANS MARTIN, Laura
MANN, Gregory
PESCHKE, Theo
STANGER, Frédéric Valentin
ALVIZO, Oscar
SUBRAMANIAN, Nandhitha
Priority Data
PCT/CN2023/071908
12.01.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5693 | |
| EPO | Filing, Examination, Granting | 109564 | |
| Japan | Filing, Examination, Granting | 4853 | |
| South Korea | Filing, Examination, Granting | 8168 | |
| USA | Filing, Examination, Granting | 33840 |
Total:
162,118
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides engineered ketoreductase enzymes having improved enzymatic activity including the ability of selectively reducing tert-butyl rel-(3aR,6aS)-5- oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate to tert-butyl rel-(3aR,5s,6aS)-5- hydroxyhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes.[French]
La présente invention concerne des enzymes cétoréductases modifiées ayant une activité enzymatique améliorée y compris la capacité de réduire sélectivement le rel-(3aR,6aS)-5-oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate de tert-butyle en rel-(3aR,5s,6aS)-5-hydroxyhexahydrocyclopenta[c]pyrrole -2(1H)-carboxylate de tert-butyle. L'invention concerne également des polynucléotides codant pour les enzymes cétoréductases modifiées, des cellules hôtes capables d'exprimer les enzymes cétoréductases modifiées, et des procédés d'utilisation desdites enzymes cétoréductases modifiées.